Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Digital Transformation

Set Alert for Digital Transformation

BIO Notebook: Amgen CEO Blasts IRA, Novo Nordisk Stays Cautious On BD, And More

Insights from Day Three of the BIO International Convention in San Diego include Amgen CEO Bob Bradway taking aim at the "Innovation Reduction Act," Novo Nordisk's business development head talking about spending its semaglutide bounty, Roivant's long view on BD prospects for Immunovant's FcRn inhibitor, and more regulatory concerns around artificial intelligence. 

BIO Deals

ASCO Roundup: Looking For The Future Of Cancer Research

As the American Society of Clinical Oncology annual meeting drew to a close, Scrip spoke with industry execs about staying competitive, adjusting to policy changes and how artificial intelligence is advancing cancer R&D.

ASCO Cancer

BIO Notebook: FDA User Fees For AI Regulation, Partnering Strategy Evolves, And More

Insights from Day Two of the BIO International Convention in San Diego include the evolving pros and cons of partnering, user fees potentially supporting the FDA's AI ambitions, and J&J's view on dealmaking in 2024.

BIO Artificial Intelligence

Korea Looks To Close Gap In AI Drug Development Capabilities

Syntekabio CSO HeaKyoung Cho talks to Scrip how the AI-driven drug development situation in Korea compares with global trends and what the domestic industry needs to do to survive rising competition at home and abroad.

South Korea Interviews

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Biogen’s immunology acquisition; AstraZeneca looks to cement respiratory lead; why US FTC is tough on pharma; the US election’s impact on pharma; and how new AI tools are impacting medical affairs. 

M & A Commercial

Sanofi Cements Artificial Intelligence Ambitions With OpenAI and Formation Pact

The French drugmaker’s aim is to become the first pharma company powered by artificial intelligence at scale, and the collaborations keep coming.

Artificial Intelligence Deals

'We Are Not Waiting To Be Replaced': Medical Affairs Pros Take On GPT-4o

Faster, more powerful and able to handle voices and visual images, newly released AI platform GPT-4o could potentially accelerate many tasks currently handled by pharma firms' medical affairs professionals, who are exploring ways to keep themselves relevant while embracing the unprecedented technology, DIA China hears.

Artificial Intelligence China

Hanmi Eyes Digital Healthcare As Next Growth Engine

Hanmi’s head of new product development elucidated the leading Korean pharma firm’s digital healthcare strategy at a recent domestic forum, including plans for the country’s first medicine/DTx combo, and shared views on what is needed to improve the domestic regulatory and market environment.

South Korea Digital Health

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.

Artificial Intelligence Financing

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Asia Pacific Commercial

AI Healthcare, Medical Devices Shine In Korea Q1 Financings

After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.

South Korea Artificial Intelligence

Otsuka Progresses Digital Push With US Approval Of MDD App

Otsuka/Click’s global-first adjunctive digital therapy for depression marks another step by pharmaceutical firms going digital for psychotherapy through collaborations.

Approvals Digital Health

Merck KGaA Looks To Build Cancer ADCs With Caris’s AI Technology

Deal snapshot: The German biopharma will partner with Caris’s research arm to discover and validate novel targets for incorporation into first-in-class antibody-drug conjugates for cancer.

Deals Artificial Intelligence

Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative

South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.

South Korea Artificial Intelligence

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.

China Artificial Intelligence

Lilly, BMS, Microsoft On GenAI’s Machine-First Approach Success, Cell Therapy Use, Regulation

Machines are now generating molecules that “no human would have imagined,” heard delegates at the BioAsia 2024 summit in Hyderabad, as big pharma and tech leaders discussed the many ways in which AI is causing fundamental shift in R&D approaches.

Artificial Intelligence Research & Development
See All